Submit Blog Post

D

Dr.Umesh Laddi's Med-Chemist

Do regularly update on FDA approvals, clinical trials, new
drugs, side effects, drug discovery, synthetic chemistry,
med, chemist,

  • Rated2.4/ 5
  • Updated 1 Year Ago

FDA Approves Kalydeco (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age

Updated 5 Years Ago
By Dr.Umesh Laddi

FDA Approves Kalydeco (ivacaftor) As First And Only CFTR Modulator To Treat Eligible Infants With CF As Early As Six Months Of Age
In continuation of my update on Kalydeco (ivacaftor)  Vertex Pharmaceuticals Incorporated  announced the U.S. Food and Drug Administra...
Read More

Fda Approves Iyuzeh (latanoprost Ophthalmic Solution) For The Reduction Of Elevated Intraocular Pressure (iop) In Patients With Open-angle Glaucoma Or Ocular Hypertension

Fda Approves Rezlidhia (olutasidenib) For Relapsed Or Refractory Acute Myeloid Leukemia With A Susceptible Idh1 Mutation

Fda Approves Krazati (adagrasib) For Locally Advanced Or Metastatic Non-small Cell Lung Cancer (nsclc) With A Krasg12c Mutation

Fda Approves Olpruva (sodium Phenylbutyrate) For Patients With Urea Cycle Disorders

Fda Approves Sezaby (phenobarbital Sodium Powder For Injection) For The Treatment Of Neonatal Seizures

Fda Approves Airsupra (albuterol/budesonide) Metered-dose Inhaler To Reduce The Risk Of Asthma Exacerbations

Fda Approves Sunlenca (lenacapavir) Twice-yearly Treatment For People Living With Multi-drug Resistant Hiv

Fda Approves Omlonti (omidenepag Isopropyl Ophthalmic Solution) For Reduction Of Elevated Intraocular Pressure In Primary Open-angle Glaucoma Or Ocular Hypertension

Fda Approves Iheezo (chloroprocaine Hydrochloride Ophthalmic Gel) For Ocular Surface Anesthesia

Fda Approves Relyvrio (sodium Phenylbutyrate/taurursodiol) For Patients With Amyotrophic Lateral Sclerosis (als)

Fda Approves Lytgobi (futibatinib) For Previously Treated, Unresectable, Locally Advanced Or Metastatic Intrahepatic Cholangiocarcinoma

Fda Approves Furoscix (furosemide Injection) For The At-home Treatment Of Congestion Due To Fluid Overload In Chronic Heart Failure

Biolinerx Announces Submission Of New Drug Application (nda) To Fda For Motixafortide In Stem Cell Mobilization

Cidara Therapeutics Announces Fda Acceptance For Priority Review Of New Drug Application For Rezafungin For The Treatment Of Candidemia And Invasive Candidiasis

Specific Sequence Of Drugs Reduces Cost Of Treating Metastatic Breast Cancer While Preserving Quality Of Life

Drug Turns Cancer Gene Into 'eat Me' Flag For Immune System

Smoking May Increase Odds Of Meniere Disease In Men

Common Diabetes Drug Invokana (canagliflozin) May Also Shield Kidneys, Heart

Balversa (erdafitinib) Approved For Advanced Bladder Cancer

Mayzent Approved For Relapsing Ms

Fda Approves First Generic Naloxone Nasal Spray Against Opioid Overdose

Asparagus: A Tasty Spring Veggie That Boosts Gut Health

Ginger: A Flavorful And Healing Root

Could Diabetes Drug Metformin Help Keep People Slim?

Long-term Antibiotic Use May Up Women's Odds For Heart Trouble

Veggies, Fruits And Grains Keep Your Heart Pumping

Fda Approves Mavenclad (cladribine) Tablets For Multiple Sclerosis

Fda Approves Avaclyr (acyclovir Ophthalmic Ointment) For The Treatment Of Herpetic Keratitis

Fda Approves Duaklir Pressair

Fda Approves Ibrance (palbociclib) For The Treatment Of Men With Hr+, Her2- Metastatic Breast Cancer

Fda Approves Mavenclad (cladribine) Tablets For Multiple Sclerosis

Fda Approves Mayzent (siponimod) For Secondary Progressive Multiple Sclerosis

Fda Approves Mavenclad (cladribine) Tablets For Multiple Sclerosis

Fda Approves Mavenclad (cladribine) Tablets For Multiple Sclerosis

Fda Approves Dovato (dolutegravir/lamivudine) For Hiv-1 Infection

Fda Approves Zulresso (brexanolone) For The Treatment Of Postpartum Depression

Dual-drug Therapy May Boost Odds Against A Tough Breast Cancer

Mavenclad Approved For Multiple Sclerosis

Celgene Submits Application To Fda For Ozanimod For The Treatment Of Relapsing Forms Of Multiple Sclerosis

Eisai And Imbrium Therapeutics Announce U.s. Fda Filing Acceptance Of New Drug Application For Lemborexant For The Treatment Of Insomnia

TAGS

New Blog Posts